Navigation Links
MAP Pharmaceuticals' Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
Date:9/10/2009

Monday, September 14, 2009 at 7:15 a.m. ET to review the data presented at the 14th Congress of the International Headache Society. The webcast will be accessible in the Investor Relations section of the company's website at www.mappharma.com.

About LEVADEX(TM)

LEVADEX orally inhaled migraine therapy is a novel migraine therapy candidate in Phase 3 development. Patients administer LEVADEX themselves using the company's proprietary TEMPO(R) inhaler. LEVADEX is designed to be differentiated from existing migraine treatments. It is a novel formulation of dihydroergotamine (DHE), a drug used intravenously in clinical settings to effectively and safely treat migraines. Based on clinical results, the company believes that LEVADEX has the potential to provide both fast onset of action and sustained pain relief and other migraine symptom relief in an easy-to-use and non-invasive at-home therapy.

LEVADEX is designed to incorporate the multiple beneficial mechanisms of action that allow DHE to block initiation of migraine, limit pain, reduce inflammation and stop a migraine at any point in the migraine cycle. Based on research to date, including the FREEDOM-301 trial, which was the first Phase 3 trial of LEVADEX, the company believes the unique pharmacokinetic profile of LEVADEX has the potential to effectively treat migraine, while minimizing the side effects commonly seen with DHE and other currently available medicines.

About Migraine

Migraine is a common, debilitating neurological disorder that affects approximately 30 million people in the United States, according to the National Headache Foundation. Limitations of oral triptans, the class of prescription drugs widely used for migraines, include slow onset of significant pain relief between 45 and 90 minutes, substantial variability in patient re
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... PLEASANTON, Calif. , April 28, 2015  Clinicians ... Boise, Idaho , will demonstrate that Leaf Healthcare,s ... with a caregiver,s pressure ulcer prevention turn protocols. Their ... Wound Care in San Antonio, Texas ... will present a poster entitled "Optimizing patient turning resources ...
(Date:4/28/2015)... April 28, 2015 Exagen Diagnostics, Inc., ... significant unmet need for the accurate diagnosis and ... announced today that its Avise SLE+ Connective Tissue ... orders since launch, and that adoption continues to ... identifying Connective Tissue Disease (CTD), including, but not ...
(Date:4/28/2015)... 2015 New and more complex medicines ... of manufacturers, payers, pharmacists and patients. Now ... premiere journal, is partnering with the National Association ... association dedicated solely to this developing field, to ... this growing need. "This partnership provides ...
Breaking Medicine Technology:VA Presentation at Wound Symposium to Show New Wireless Patient Monitoring System Improves Pressure Ulcer Turn Compliance 2VA Presentation at Wound Symposium to Show New Wireless Patient Monitoring System Improves Pressure Ulcer Turn Compliance 3VA Presentation at Wound Symposium to Show New Wireless Patient Monitoring System Improves Pressure Ulcer Turn Compliance 4Exagen Sees Growing Adoption of Avise Diagnostic for Connective Tissue Disease with New Milestone 2Specialty Pharmacy Times Partners With National Association of Specialty Pharmacy to Improve Care for Patients 2Specialty Pharmacy Times Partners With National Association of Specialty Pharmacy to Improve Care for Patients 3Specialty Pharmacy Times Partners With National Association of Specialty Pharmacy to Improve Care for Patients 4
... The nationwide launch of the Recovery Audit Contractor (RAC) program ... sizes and types are busy preparing for it as not ... findings resulting in money owed to Medicare. Think adding staff ... with mountains of new work. Designed based on the experiences ...
... Bionovo Inc. (Nasdaq: BNVI ) announced today the ... effect of tamoxifen on estrogen receptor beta (ERb) gene ... published in Molecular and Cellular Endocrinology, demonstrate that tamoxifen ... of breast cancer cell proliferation. , "Tamoxifen has ...
Cached Medicine Technology:American Hospital Association (AHA) Names OnBase 'RACTrac Compatible' 2American Hospital Association (AHA) Names OnBase 'RACTrac Compatible' 3Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta 2Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta 3
(Date:4/28/2015)... PA (PRWEB) April 28, 2015 Helping ... decision-making process when a loved one dies can be ... the funeral arrangements and final tribute can ... families in need, Beinhauer Family Funeral Homes ... services offered to families by doubling its number of ...
(Date:4/28/2015)... 28, 2015 Two leaders in patient ... to Becker's Hospital Review’s list of 50 Experts ... Pronovost, M.D., Ph.D. , director of the Armstrong ... vice president for patient safety and quality at Johns ... vice president of medical affairs and chief patient safety ...
(Date:4/28/2015)... Georgia State University’s School of Public ... will partner with the school on efforts to improve ... that produces more tobacco and has more smokers than ... Tobacco Control Partnership-Tobacco Free Cities, will focus on a ... support tobacco control efforts and where public health organizations ...
(Date:4/28/2015)... 2015 Vancouver personal injury lawyers at ... it is smarter to call an attorney before calling ... The blog reasons that there are several benefits of ... well-versed with the law and can help clients reach ... to on their own. Competent and experienced personal injury ...
(Date:4/28/2015)... 28, 2015 The biologics safety testing ... drivers for the market include growth of the pharmaceutical ... drug launches. Over the years, the number of drug ... and 2010, the FDA approved 225 drug applications and ... Europe accounted for 3,822 of the pharmaceutical and 1,998 ...
Breaking Medicine News(10 mins):Health News:Beinhauer's Increasing Number of Celebrants to Meet Growing Demand for Personalized Funeral Ceremonies 2Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 2Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 3Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 4Health News:Georgia State Names Partner Cities For Tobacco Control Project 2Health News:Vancouver Personal Injury Lawyers Recently Stated in Latest Blog That It Is Smarter To Call A Lawyer Before ICBC 2Health News:Biological Safety Testing Market, By Application Product & Test – Global Forecast 2019 - Report Released by MarketsandMarkets 2Health News:Biological Safety Testing Market, By Application Product & Test – Global Forecast 2019 - Report Released by MarketsandMarkets 3Health News:Biological Safety Testing Market, By Application Product & Test – Global Forecast 2019 - Report Released by MarketsandMarkets 4
... STAMFORD, Conn., Aug. 27 American children miss more ... other two diseases combined.(1) As parents help their kids prepare for ... a lifetime of good oral health with the new Philips Sonicare ... Sonicare For Kids is specially designed to support kids, needs at ...
... , DES PLAINES, Ill. and NEW ... into an agreement with Pfizer Inc to develop a molecular diagnostic ... the presence of gene rearrangements. Pfizer has developed a novel ... of many cancers. To be eligible to receive Pfizer,s oral ...
... those with deceased donor transplant organs, study shows , ... disease may do just as well receiving treatment at ... donor, new research has found. , Researchers in Canada ... had either received a kidney transplant from a deceased ...
... , , , ... and CHATTANOOGA, Tenn., Aug. 27 Sandata Technologies, Inc., a ... healthcare and social services communities, and Volunteer State Health Plan ... announced an agreement by which VSHP will use Sandata,s IntegriCare ...
... China, Aug. 27 /PRNewswire-Asia/ -- On August 10, 2009, Winner,Medical ... entered into a contract with a machine producer in China ... This new machineries will constitute the ... operated in the Company,s,subsidiary in Huanggang, and it is expected ...
... , , CUPERTINO, Calif., ... today reported that it has signed an exclusive long term ... Inc. (NYSE: KG ). This agreement stipulates the ... based on DURECT,s manufacturing cost plus a specified percentage mark-up, ...
Cached Medicine News:Health News:Keep Oral Health in Check This School Year With the New Philips Sonicare for Kids Power Toothbrush 2Health News:Keep Oral Health in Check This School Year With the New Philips Sonicare for Kids Power Toothbrush 3Health News:Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy 2Health News:Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy 3Health News:Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy 4Health News:Home Dialysis a Good Option for Kidney Disease Patients 2Health News:Sandata Selected by Volunteer State Health Plan to Manage TennCare Choices 2Health News:Winner Medical Purchased New Purcotton Production Line to Meet Increasing Demand 2Health News:Winner Medical Purchased New Purcotton Production Line to Meet Increasing Demand 3Health News:DURECT Signs Long Term Excipient Supply Agreement With King Pharmaceuticals for REMOXY(R) 2Health News:DURECT Signs Long Term Excipient Supply Agreement With King Pharmaceuticals for REMOXY(R) 3Health News:DURECT Signs Long Term Excipient Supply Agreement With King Pharmaceuticals for REMOXY(R) 4
... Stylish and comfortable eye protection Properly ... 90% of scatter radiation. Our high quality ... and comfort with minimized weight. Our lenses ... optics that meet all industry standards. Most ...
... protection Properly manufactured radiation protective eyewear ... Our high quality frames and materials offer ... weight. Our lenses are made of Schott ... industry standards. Most Pulse Glasses are offered ...
... lenses and frames are designed with the safety ... lenses are Schott RS-520 (also called SF-6) leaded ... These lenses meet standards, as set for optical ... ,While our eyewear is protecting your eyes, ...
... and frames are designed with the safety and ... are Schott RS-520 (also called SF-6) leaded glass, ... lenses meet standards, as set for optical clarity, ... ,While our eyewear is protecting your eyes, it ...
Medicine Products: